Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 634 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Zooming in: Fine-tuning the picture to diagnose oesophageal cancer earlier August 10, 2021 Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically... August 8, 2023 Bjorn Saven: “By supporting early career researchers to do their jobs... November 19, 2021 How can we diagnose more cancers earlier? July 27, 2021 Load more HOT NEWS Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre... FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or... Cancer in My Community: Advancements in Cancer Care in Singapore How I Learned to Advocate for Myself During Cancer: “Your Stories”...
